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Abstract. Background/Aim: Constitutive activation of
nuclear factor kappa-B (NFĸB) is a hallmark of various
cancer types, including melanoma. Chemotherapy may
further increase tumour NFĸB activity, a phenomenon that,
in turn, exacerbates drug resistance. This study aimed at
preliminary screening of a panel of aromatic aldehydes,
including vanillin, for cytotoxicity and suppression of tumour
cell NFĸB activity. Materials and Methods: The cytotoxic and
NFĸB-inhibitory effects of 10 aromatic aldehydes, including
vanillin, were investigated in cultured A375 human melanoma
cells. Each compound was assayed alone and in combination
with the model NFĸB-activating drug doxorubicin. The most
promising analogues were then tested alone and in
combination with 4-hydroperoxycyclophosphamide in vitro,
and with cyclophosphamide in mice bearing A375 xenografts.
Results: The vanillin analogues o-vanillin and 2,4,6-
trihydroxybenzaldehyde exhibited cytotoxicity against
cultured A375 cells, and inhibited doxorubicin- and 
4-hydroperoxycyclophosphamide-induced NFĸB activation.
They also suppressed A375 cell growth in mice. Conclusion:
o-vanillin and 2,4,6-trihydroxybenzaldehyde deserve further
evaluation as potential anticancer drugs.
Nuclear factor kappa-B (NFĸB) is a transcription factor
playing a crucial role in malignant diseases (1-4). Up-
regulation of NFĸB activity is detected in various human
tumours (5-7), including pancreatic adenocarcinoma (8),
breast cancer (9), and melanoma (10), where it may
contribute to malignant behaviour. In particular, NFĸB
activation has been associated with cancer development and
progression (5, 11), and may inhibit apoptosis and favour
cancer cell proliferation, invasion, angiogenesis, and
metastasis (12, 13). Importantly, increased NFĸB activation
may induce tumour immune escape and chemotherapy
resistance (14-16). Chemotherapy-induced cellular stress, in
turn, might further increase NFĸB activity of tumour cells,
protecting them from chemotherapy-induced apoptosis (17-
19). Therefore, NFĸB signaling pathways could serve as
potential targets for cancer therapy. 
Vanillin (4-hydroxy-3-methoxybenzaldehyde; compound
10, Table I) is a major component of the bean and pod of
some plant species of the Vanilla genus, and is also
synthesized on a large scale for use as a flavouring agent in
food, fragrance and pharmaceutical industries. Multiple
biological effects have been documented for vanillin. It
exhibits antioxidant (20, 21), antimicrobial (22), analgesic
(23, 24) and anti-sickling (25) properties. It was also proven
to be an anticarcinogen in rats (26) and an antimutagen in a
variety of in vitro models (27-29). Vanillin is relatively non-
cytotoxic towards cultured mammalian cells, but does
potentiate the cytotoxicity of some DNA-damaging agents,
including cisplatin (30) and mitomycin C (31), a property
which correlates with its ability to impair DNA double-strand
break repair via inhibition of DNA protein kinase (30).
Although unable to suppress primary tumour growth itself,
vanillin was found to exert anti-metastatic activity in the 4T1
mouse mammary carcinoma spontaneous metastasis model,
and to inhibit tumour cell invasion and migration in vitro
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(32). More recently, vanillin was found to inhibit
angiogenesis in a chick chorioallantoic membrane assay (33),
and to suppress NFĸB activation induced by various
inflammatory stimuli including tumour necrosis factor-
related apoptosis-inducing ligand, tumour necrosis factor α
(34), trinitrobenzene sulfonic acid (35), and 12-O-
tetradecanoylphorbol-13-acetate (36). The suppressive effect
of vanillin on NFĸB activity may be a major mechanism
underlying its anti-invasive, anti-metastatic and
antiangiogenic properties, and offers potential for developing
novel anticancer agents. In particular, we reasoned that
although vanillin itself exhibits little cytotoxic activity (30),
it might sensitize tumour cells to anticancer drugs known to
elicit NFĸB activation, thus increasing the efficacy of
chemotherapy regimens, as well as serve as a lead structure
for the discovery of more effective analogues.
In this article, we report the results of in vitro experiments
undertaken to screen a small set of structurally related
aromatic aldehydes, including vanillin, for cytotoxic activity,
and for inhibition of constitutive and chemotherapy-induced
NFĸB activity in human melanoma cells. Furthermore, we
report the results of a trial in A375 human melanoma-bearing
mice evaluating the efficacy of two selected aldehydes,
namely o-vanillin and 2,4,6-trihydroxybenzaldehyde, as
single agents and in combination with the NFĸB-inducing
drug cyclophosphamide.
Materials and Methods
Chemicals and working solutions. The anticancer drugs doxorubicin
(as hydrochloride salt) and cyclophosphamide, as well as all the
aromatic aldehydes used throughout the study, including vanillin (4-
hydroxy-3-methoxybenzaldehyde; compound 10), the vanillin isomer
o-vanillin (2-hydroxy-3-methoxybenzaldehyde; compound 7), and
2,4,6-trihydroxybenzaldehyde (compound 6) (see Table I), were
obtained from Sigma-Aldrich (St. Louis, MO, USA). 4-
Hydroperoxycyclophosphamide (4-HC) was obtained from Niomech-
IIT GmbH (Bielefeld, Germany). Stock solutions of each aldehyde at
100 mM were prepared in dimethyl sulfoxide (DMSO; Sigma-
Aldrich), stored at 4˚C, and used within 6 weeks. Working solutions
were prepared just before use by dilution of the stocks with cell
culture medium (see below); the final concentration of DMSO in the
culture medium never exceeded 0.25% (v/v). Suspensions for oral
administration of o-vanillin and 2,4,6-trihydroxybenzaldehyde (TBA)
were prepared just before use by dilution of the stock solutions with
sterile phosphate-buffer saline (PBS). A stock solution of doxorubicin
at 10 mM was prepared in sterile sodium chloride 0.9% and kept at
−20˚C. 4-HC and cyclophosphamide were dissolved in sterile PBS
immediately before use.
Cell culture and transfection. The A375 human melanoma cell line
was originally obtained from the American Type Culture Collection,
(Manassas, VA, USA) and maintained in Dulbecco’s modified
Eagle’s medium/nutrient mixture F-12 (DMEM/F12) medium
(Lonza, Basel, Switzerland) supplemented with 10% heat-
inactivated foetal bovine serum (FBS; Lonza). Cultures were grown
at 37˚C in a humidified atmosphere consisting of 5% CO2/95% air.
The NFĸB reporter cell lines were obtained by transfection with the
pNFĸB-Luc/neo reporter construct using Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA, USA). In the Luciferase Assay
System, the firefly luciferase was used as a reporter because the
assay is very sensitive, has no background and the reporter activity
is available immediately upon translation. As a transfection efficacy
control, we used a plasmid encoding enhanced green fluorescent
protein (pEGFP; Invitrogen); the transfection efficacy with the
pEGFP vector was 78%, as determined by flow cytometry 48 hours
after transfection. Transfected cells were selected in the presence of
G418 (200 μg/ml; Sigma).
Testing of NFĸB activity in A375 cells stably transfected with an
NFĸB-luciferase reporter construct. A375 cells stably transfected with
the pNFĸB-Luc/neo indicator construct were plated at 3×104/well on
TC quality luminescent assay plates (Corning Incorporated, NY,
USA) in 200 μl of DMEM/F12 medium supplemented with 10%
heat-inactivated FBS. After one-day culturing, the cells were treated
with 10, 5, 2.5, 1.25, or 0.625 μM doxorubicin in the absence or in
the presence of 250 μM of each of the selected aldehydes. 4-HC was
also tested at 50, 25, 12.5, 6.25 and 3.125 μM concentration alone
and in combination with TBA or o-vanillin at 250 μM. After 6-hour
incubation (37˚C; 5% CO2), the medium was discarded; the cells
were washed with 200 μl PBS/well (Promo Cell, Heidelberg,
Germany) and lysed with 20 μl Cell Culture Lysis Reagent/well
(Promega, Madison, WI, USA) for 5 minutes. After adding the firefly
luciferase substrate (20 μl/well; Promega), luciferase activity was
measured with Luminoscan Ascent Scanning Luminometer (Thermo
Electron Corporation, Waltham, MA). Aldehydes exhibiting inhibition
of drug-induced or constitutive (basal) NFĸB activity greater than
20% were considered active compounds.
Cell viability assay. A375 human melanoma cells were seeded into
flat-bottomed 96-well plates (1×104 cells/well) and allowed to
attach for 24 h. They were then grown (37˚C; 5% CO2) for an
additional 48 h in the absence (control) or in the presence of 250
μM of the tested aromatic aldehyde, or in the presence of increasing
concentrations of doxorubicin (0.625-10 μM) or 4-HC (3.125-50
μM). Cell viability was then assessed using an XTT colorimetric
assay (Cell Proliferation Kit XTT; AppliChem, Darmstadt,
Germany) that measures the activity of dehydrogenase enzymes of
viable cells (37). Within each experiment, determinations were
performed in duplicate or triplicate, and experiments were repeated
at least five times. The percentage cell viability was defined as the
absorbance of the drug-treated wells expressed as a percentage of
that of controls.
Animals. Twelve- to sixteen-week-old male NSG mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) were purchased from Charles River
Hungary Ltd. (Budapest, Hungary). They were maintained in the
specific pathogen-free animal facility of the Biological Research
Center (BRC, Szeged, Hungary). Six- to eight-week-old inbred male
Balb/c mice were obtained from the animal facility of the BRC.
They received commercial mouse food pellets and water ad libitum. 
In vivo experiments. All the animal experiments were performed
according to Institutional and National Animal Experimentation and
Ethics Guidelines, in possession of an ethical clearance (number:
XVI./03521/2011).
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Table I. Cytotoxic and nuclear factor kappa-B-inhibitory effects of different aromatic aldehydes in A375 human melanoma cells. 
#Cell viability was evaluated after continuous 48-h exposure to aldehyde or aldehyde plus doxorubicin. Data reported are means of 3-5 experiments.
†Luciferase activity was evaluated after a 6 h-exposure time. Data reported are means of 3-5 determinations. *Doxorubicin concentration was 1.25
μM; §exposure to doxorubicin (1.25 μM) alone resulted in 15% cell viability.
Explorative toxicology study. The in vivo antitumor activity trial was
preceded by an explorative multiple-dose toxicology study carried
out in healthy male Balb/c. Animals were randomly assigned to each
experimental group (n=3/group) and were treated once a day orally
with o-vanillin (60 mg/kg), TBA (60 mg/kg), or PBS (control) for
5 consecutive days followed by a 2-day wash-out. Mice were
examined daily for a decrease in physical activity, weight loss, and
other signs of disease. After 3 weeks of treatment, the animals were
sacrificed and major organs (intestine, liver, kidneys, spleen, heart,
and lungs) were visually inspected for any abnormalities. Treatment-
related signs of toxicity were not observed, neither during the 14-
day treatment period, nor at macroscopic post-mortem examination.
A375 xenograft and treatment. NSG mice were subcutaneously
injected with 2×106 A375 cells suspended in 100 μl of RPMI
1640 (Lonza). One day later, the animals were randomly assigned
to the following experimental groups (n=5-8/group): a: o-vanillin
(60 mg/kg); b: cyclophosphamide (80 mg/kg); c: o-vanillin
(60 mg/kg) plus cyclophosphamide (80 mg/kg); d:TBA (60
mg/kg); e: TBA (60 mg/kg) plus cyclophosphamide (80 mg/kg);
f: control group. The aldehydes were administered once a day
orally for 5 consecutive days followed by a 2-day wash-out,
starting 2 days after tumour implantation. Cyclophosphamide was
administered intraperitoneally (i.p.) on day 7 and 14 after tumour
cell injection; the dose and schedule of cyclophosphamide were
chosen on the basis of previous optimal dose/schedule-finding
experiments, which had been carried out in mice bearing 4T1
mouse mammary carcinomas (Vizler et al., unpublished data).
Tumour volume was estimated from measurements made with a
calliper using the formula: tumour volume (mm3)=D × d2; where
D and d values were the longest and the shortest diameters of the
tumour, respectively. For ethical reasons, all the animals were
sacrificed at day 20.
Results
Selected vanillin analogues remarkably inhibit NFĸB
activation and A375 human melanoma cell growth in vitro.
Two widely used anticancer drugs capable of inducing NFĸB
activity are doxorubicin and cyclophosphamide (38). A set
of experiments analyzed the impact of doxorubicin on NFĸB
activity in A375 human melanoma cells stably transfected
with an NFĸB luciferase reporter construct, both in the
absence and in the presence of a fixed concentration (250
μM) of each of the 10 selected aromatic aldehydes;
luciferase activity was evaluated after a 6 hour-exposure
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Figure 1. Effects of doxorubicin and selected aromatic aldehydes on
nuclear factor kappa-B (NFĸB) activity of A375 human melanoma cells
stably transfected with a NFĸB-luciferase reporter construct
(A375/NFĸB-Luc cells). The dotted line represents the NFĸB activity of
untreated cells (basal NFĸB activity). A: Doxorubicin (1.25 μM) caused
a more than 3-fold increase of NFĸB activity compared to control
(p<0.0001). B: o-vanillin (compound 7; final concentration: 250 μM)
significantly reduced basal NFĸB activity of A375/NFĸB-Luc cells
(p<0.0001 vs. control). On the contrary, vanillin (compound 10; final
concentration: 250 μM) and TBA (compound 6; final concentration:
250 μM) did not significantly affect basal NFĸB activity of A375/NFĸB-
Luc cells. C: Induction of NFĸB activity by 1.25 μM doxorubicin was
significantly suppressed by 250 μM 2,4,6-trihydroxibenzaldehyde
(compound 6; p=0.0020 vs. doxorubicin alone) or 250 μM o-vanillin
(p<0.0001 vs. doxorubicin alone). Values are mean±SD (n=3).
Statistical comparison was performed by unpaired, two tailed t-test. 
time. As shown in Figure 1A, the maximum inductive effect
of doxorubicin was observed at 1.25 μM, resulting in a more
than 3-fold increase in luciferase activity over the basal
level. This doxorubicin concentration was, therefore, selected
for the subsequent assays. Six out of the 10 tested aldehydes
(namely compounds 1, 3, 5, 6, 7 and 9) but not vanillin
(compound 10) were effective in inhibiting the induction of
NFĸB transcriptional activity by doxorubicin by more than
20%. Results of these experiments are summarized in the last
column of Table I. Interestingly, a vanillin isomer, o-vanillin
(compound 7), was the most potent compound, inhibiting
doxorubicin-mediated induction of NFĸB activity by 65%
(Figure 1C). This aldehyde was also active in suppressing
constitutive (basal) NFĸB activity in A375 cells (Figure 1B).
The inhibitory effect of o-vanillin (compound 7) on
chemotherapy-induced NFĸB activity in A375 human
melanoma cells was confirmed using 4-
hydroperoxycyclophosphamide (4-HC), an in vitro active
analogue of the prodrug cyclophosphamide, as the NFĸB
activator. The maximum induction of luciferase activity by
4-HC occurred at 12.5 μM, where 250 μM o-vanillin
suppressed 4-HC-induced activity by 43% (Figure 2). Based
on the results of the in vitro tumour cell growth-inhibition
assay (see below), a second benzaldehyde derivative, namely
TBA (compound 6), was evaluated for its ability to
counteract NFĸB induction by 4-HC; 250 μM TBA inhibited
4-HC-elicited induction of NFĸB by 17% (data not shown).
The same aromatic aldehydes were further examined in
vitro at a fixed concentration (250 μM) for cytotoxicity as
single agents and in combination with the NFĸB-activating
anticancer agent doxorubicin; cell viability was evaluated
using an XTT assay after a continuous 48-h exposure to the
studied compounds. Results of these studies are summarized
in Table I. Among the tested aldehydes, only TBA and o-
vanillin exhibited remarkable cytotoxicity when tested alone,
reducing A375 cell viability to 10% or less when combined
with 1.25 μM doxorubicin (Table I). 
o-Vanillin and TBA exert significant therapeutic activity in
mice bearing A375 human melanoma xenografts. Based on
the above-described in vitro findings, o-vanillin and TBA
were selected for an in vivo efficacy trial in tumour-bearing
mice, as single agents and in combination with
cyclophosphamide; the dose and schedule of administration
of the studied aldehydes were based on the results of an
explorative toxicology study carried out in Balb/c mice,
demonstrating no gross toxicity signs and weight loss.
As shown in Figure 3, oral administration of o-vanillin, or
TBA, as a single agent or in combination with i.p.
cyclophosphamide, delayed the growth of A375 human
melanoma xenografts in immunodeficient NSG mice (see
legend of Figure 3 for details on the doses and schedules of
administration of each agent). It is worth noting that the
growth-delaying effect of the combination o-vanillin/
cyclophosphamide reached statistical significance by day 15,
and remained statistically significant until the end of the
experiment (i.e. day 20). Moreover, on day 20, the antitumor
effect of both tested aldehydes, as single agents, was strongly
significant; the growth inhibition was 45% in the case of
TBA and 32% in the case of o-vanillin, respectively
(p<0.0001 vs. control). Importantly, it was comparable to that
exerted by the established anticancer drug cyclophosphamide.
Finally, the statistical analysis showed that on day 20, the
combination of o-vanillin and cyclophosphamide was more
effective than o-vanillin alone (p<0.05).
Discussion
NFĸB signaling pathways are constitutively active in many
tumour types and have been implicated in cancer cell
proliferation, invasion, metastasis and angiogenesis, as well as
in suppression of cancer cell apoptosis (12). Moreover, some
anticancer agents may induce chemoresistance of cancer cells
through activation of NFĸB (14, 16, 17).Therefore, NFĸB is
currently considered an ideal target for cancer therapy (2), and
various NFĸB inhibitors targeting different components of
NFĸB activation, that is, inhibitor of kappa B kinase or NFĸB
subunits, are under development (39).
The observation that the widely-used natural flavouring
agent vanillin (4-hydroxy-3-methoxybenzaldehyde; compound
10, Table I) behaves as an NFĸB inhibitor in both in vitro and
in vivo preclinical models (34-36) led us to explore the ability
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Figure 2. Impact of o-vanillin (compound 7; final concentration, 
250 μM) on 4-hydroperoxycyclophosphamide (4-HC)-induced NFĸB
activity in A375/NFĸB-Luc cells. The dotted line represents the NFĸB
activity of untreated cells (basal NFĸB activity). The maximum
induction of NFĸB activity was observed at 12.5 μM 4-HC, where o-
vanillin reduced the drug induced NFĸB activity by 43%. Values are
mean±SD (n=3).
of a small panel of aromatic aldehydes, including vanillin, to
suppress chemotherapy-induced NFĸB activity, and to inhibit
tumour cell growth. Even though, surprisingly, vanillin was
ineffective in modulating NFĸB activity under our
experimental conditions, six out of the 10 tested aldehydes
(namely compounds 1, 3, 5, 6, 7 and 9) were effective in
suppressing NFĸB induction by the anticancer drug
doxorubicin in cultured A375 human melanoma cells (Table
I), with o-vanillin, a naturally occurring isomer of vanillin
(40), being the most potent compound (Table I, and Figure
1C). The remarkable anti-NFĸB activity exhibited by
o-vanillin as well as its significant tumour growth-inhibiting
activity both in vitro (Table I) and after oral administration at
a non-toxic schedule to mice bearing A375 human melanoma
xenografts (Figure 3) suggest that this vanillin analogue
deserves further preclinical investigation as a potential
antitumor drug. Although toxicological data on o-vanillin are
scant, the published data of acute oral toxicity in mice (median
oral lethal dose: 1330 mg/kg) (41), together with the results
of our explorative multiple-dose toxicology study, make this
compound promising in terms of host toxicity potential.
Besides o-vanillin, our screening highlighted the
aromatic aldehyde TBA, as a compound endowed with
both a moderate ability to counteract induction of NFĸB
activity by doxorubicin or 4-HC in A375 human melanoma
cells, and a remarkable in vitro and in vivo growth-
inhibitory activity towards the same cell line (Table I and
Figure 3). TBA is one several metabolites of anthocyanins
formed by gut microflora (42), and has been recently
found to exhibit both in vitro antiproliferative activity
towards human colorectal cancer cell lines, as well as an
inhibitory effect on NFĸB DNA-binding activity in Caco-
2 cells (43).
In conclusion, a preliminary screening of a small panel of
vanillin analogues for tumour growth inhibition and
suppression of NFĸB signalling in A375 human melanoma
cells has led to the identification of o-vanillin and TBA as
compounds deserving further preclinical evaluation as
potential anticancer agents both alone and in combination
regimens. We plan to perform systematic preclinical studies
in order to further explore the anticancer potential of the
selected aldehydes, as well as to clarify the role of NFĸB
inhibition in their antitumor activity. 
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Figure 3. Effect of o-vanillin (compound 7), TBA (compound 6), cyclophosphamide (CP), o-vanillin plus CP, and TBA plus CP on A375 growth in
NSG mice. A375 human melanoma cells were injected subcutaneously in the abdominal fat pad of NSG mice (day 0). One day later, the animals
were randomly assigned to an experimental group (n=5-8). Compound 6 and 7 were administered orally daily at 60 mg/kg/day for 5 consecutive
days followed by a 2-day wash-out, starting 2 days after tumour implantation. Cyclophosphamide was administrated intraperitoneally at day 7 and
14 after tumour cell injection. Tumour volumes were evaluated as described in the Materials and Methods Section. Data are mean tumour volume
(mm3); bars, standard deviation. Results were analyzed using two-way ANOVA followed by Bonferroni post-test. *p<0.05 vs. control; **p<0.01 vs.
control; #p<0.01 vs. control; †p<0.05 vs. compound 6 alone. 
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